Peripheral blood GATA2 expression impacts RNF213 mutation penetrance and clinical severity in moyamoya disease

Area of Science:

• Genetics and Molecular Biology
• Neuroscience
• Immunology

Background:

• The RNF213 p.R4810K founder mutation increases susceptibility to moyamoya disease (MMD) and intracranial artery disease.
• Incomplete penetrance of this mutation suggests unknown molecular mechanisms influence disease development.
• Understanding these mechanisms is crucial for predicting disease risk and severity.

Purpose of the Study:

• To investigate the molecular mechanisms underlying the incomplete penetrance of the RNF213 p.R4810K mutation in MMD.
• To identify potential biomarkers associated with disease manifestation and severity.
• To explore the role of gene expression in MMD pathogenesis.

Main Methods:

• Transcriptome analysis of peripheral blood from MMD patients and unaffected carriers.
• Bayesian network analysis to identify upregulated and downregulated gene modules.
• Weighted gene co-expression network analysis and case-control studies to validate GATA2 network findings.

Main Results:

• Upregulated gene modules included lipid metabolism, leukocyte development (GATA2, SLC45A3), and EGFR signaling.
• Downregulated modules involved mitochondrial ribosomal proteins and cytotoxic T cell immunity.
• Higher GATA2 expression correlated with earlier onset, bilateral involvement, and symptomatic disease in mutation carriers.

Conclusions:

• Peripheral blood GATA2 expression is associated with increased penetrance of the RNF213 mutation in MMD.
• Elevated GATA2 levels correlate with more severe clinical manifestations of MMD.
• GATA2 may serve as a potential biomarker for MMD progression and severity.